Skip to main content

Advertisement

Table 1 Baseline demographic and disease characteristics*

From: Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: Results from the ABRAB study

  Group A (n = 49) (MTX treatment) % v. mean (SD) Group B (n = 35) (anti-TNF + MTX treatment) % v. mean (SD)
Age, (mean ± S.D.) 60.1 (13.7) 54.7 (15)
Women, n (%) 42 (85.7%) 28 (80%)
Disease duration, (month) 7.9 (2) 8.5 (1.2)
IgM RF positive, n (%) 34 (69.4%) 22 (62.9%)
Anti-CCP positive, n (%) 37 (75.5%) 26 (74.3%)
DAS28ESR , mean ± S.D. 6.1 (0.9) 6.4 (0.9)
CDAI, mean ± S.D. 36.2 (11.5) 33.6 (12.7)
Tender joint count, mean ± S.D. 13.1 (6.5) 14 (7.2)
Swollen joint count, mean ± S.D. 7.5 (5.9) 9.4 (5.2)
Patient global assessment (VAS 0–100), mean ± S.D. 65 (17.9) 64.3 (18.3)
ESR, mean ± S.D. 43.7 (22.4) 46.9 (33.5)
CRP, mean ± S.D. 27.5 (28.4) 40.3 (46.9)
HAQ-DI (0–3), mean ± S.D. 1.4 (0.7) 1.6 (0.7)
  1. *There were no statistically significant differences in any demographic or baseline characteristics between the groups, by Mann–Whitney test for continuous variables and chi-square test for dichotomous variables; statistical significance was set as p < 0.05.
  2. (RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated protein, DAS28ESR: disease activity score based on the erythrocyte sedimentation rate, CDAI: clinical disease activity index, VAS: visual analogue scale, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, HAQ-DI: Health Assessment Questionnaire - Disability Index, vdHS: van der Heijde modified Sharp score).